ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - ticagrelor - טבליות מצופות פילם - ticagrelor 90 mg - ticagrelor - ticagrelor - brilinta, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

ישראל - עברית - Ministry of Health

genmedix , israel - streptokinase - אבקה להכנת תמיסה לאינפוזיה - streptokinase 750000 iu/vial - streptokinase - streptokinase - acute myocardial infarction, deep vein thrombosis, pulmonary embolism, acute or subacute thrombosis of peripheral arteries and chronic occlusive arterial diseases, occlusion of central retinal artery or vein.

ישראל - עברית - Ministry of Health

genmedix , israel - streptokinase - אבקה להכנת תמיסה לזריקה - streptokinase 1500000 iu - streptokinase - streptokinase - systemic administration: in deep vein thromboses, lung embolism, acute myocardial infarction for re-opening of coronary vessels. in acute and subacute thromboses of peripheral arteries and chronic occlusive arterial diseases, occlusion of central retinal artery or vein. local administration: in acute myocardial infarction for re-opening of coronary vessels, in acute, subacute and chronic thromboses as well as embolisms of peripheral arteries.

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - urokinase - אבקה להכנת תמיסה לזריקה - urokinase 10000 iu - urokinase - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - urokinase - אבקה להכנת תמיסה לזריקה - urokinase 50000 iu - urokinase - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - urokinase - אבקה להכנת תמיסה לזריקה - urokinase 100,000 iu - urokinase - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - urokinase - אבקה להכנת תמיסה לזריקה - urokinase 250000 iu - urokinase - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - urokinase - אבקה להכנת תמיסה לזריקה - urokinase 500000 iu - urokinase - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.

ישראל - עברית - Ministry of Health

tzamal bio-pharma ltd - urokinase 1000000 iu - powder for solution for injection - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.

ישראל - עברית - Ministry of Health

kamada ltd, israel - plasma protein fraction - תמיסה לאינפוזיה - plasma protein fraction 200 mg/ml - protein c - protein c - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate. the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient, based on official recommendation.